期刊文献+

TLR4受体/MAPK信号通路在心源性恶病质发生机制中的作用研究进展 被引量:4

The role of Toll-like receptor 4/MAPK signal pathway in cardiac cachexia
原文传递
导出
摘要 心源性恶病质是一种发生在慢性心力衰竭终末期的严重并发症,以骨骼、肌肉和脂肪组织减少为特征。国内外的研究证实,Toll样受体4(TLR4)及丝裂原活化蛋白激酶(MAPK)通路与心力衰竭的发生及演变有着密切的联系,并直接或间接通过细胞因子的激活、神经激素分泌的调控及胰岛素抵抗等参与心源性恶病质的发生。本文就TLR4/MAPK信号通路在心源性恶病质发生机制中的作用予以综述,以期对今后心源性恶病质的临床治疗提供一定的理论依据。 Cardiac cachexia is one of the severe complications occurring in end-stage chronic heart failure,characterized by reduction of bone,muscle and fat tissue.Many domestic and foreign researchers have demonstrated that toll-like receptor 4and mitogen-activated protein kinase pathway are closely related with the occurrence and development of heart failure via directly or indirectly by activation of cytokine,regulation of neurohormone secretion,insulin resistance and therefore,participate in the occurrence of cardiac cachexia.In the paper,we aim to provide a theoretical basis for cardiac cachexia treatment by review the role of toll-like receptor 4/MAPK signal pathway in cardiac cachexia.
作者 赵欣 张昕
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2015年第10期1035-1039,共5页 Journal of Clinical Cardiology
关键词 心源性恶病质 TOLL样受体4 丝裂原活化蛋白激酶通路 肿瘤坏死因子Α cardiac cachexia Toll like receptor-4 mitogen-activated protein kinase pathway tumor necrosis factorα
  • 相关文献

参考文献28

  • 1ANKER S D, NEGASSA A, COATS A J, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin- converting-enzyme inhibitors: an observational study [J]. Lancet, 2003, 361: 1077-1083.
  • 2ANKER S D, LAVIANO A, FILIPPATOS G, et al. ESPEN Guidelines on Parenteral Nutrition: on cardi- ology and pneumology [J]. Clin Nutr, 2009, 28: 455-460.
  • 3ROZENTRYT P, VON HAEHI.ING S, LAIN- SCAK M, et al. The effects of a high-caloric protein- rich oral nutritional supplement in patients with chro- nic heart failure and cachexia on quality of life, body composition, and in(lamination markers: a random- ized, double-blindpilot study [J]. Cachexia Sarcope- nia Muscle, 2010, 1: 35-42.
  • 4SPRINGER J, ADAMS V, ANKER S D. Myosta- tin: Regulator of muscle wasting in heart failure and treatment target for cardiac cachexia [J]. Circula- tion, 2010, 26, 121:354-356.
  • 5PUREZA V, FLOREA V G. Mechanisms for ca chexia in heart failure [J]. Curr Heart Fail Rep, 2013, 10: 307-314.
  • 6YOSHIDA T, TABONY A M, GALVEZ S, et al. Molecular mechanisms and signaling pathways of an- giotensin II-induced musclewasting: potential thera- peutic targets for cardiac cachexia [J]. Int J Biochem Cell Biol, 2013, 45: 2322-2332.
  • 7TOTH M J, LEWINTER M M, ADES P A, et al. Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation [J]. Clin Sci (Lond), 2010, 119: 467-476.
  • 8VON HAEHI.ING S, I.AINSCAK M, SPRINGER J, et al. Cardiac cachexia: a systematic overview [J]. Pharmacol Ther, 2009, 121: 227-252.
  • 9LEVINE B, KALMAN J, MAYER L, et al. Elevat- ed circulating levels of tumor necrosis factor in severe chronic heart failure [J]. N Engl J Med, 1990, 323: 236-241.
  • 10MARTINS T, VITORINO R, MOREIRA-GON- CAI.VES D, et al. Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia [J]. Clin Biochem, 2014, 47: 8-15.

同被引文献48

引证文献4

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部